GigaGen one of "Best Places to Work in the Bay Area"

GigaGen one of "Best Places to Work in the Bay Area"

In the San Francisco Business Times’s annual survey.

BillionToOne Beats the Odds With $15 Million Series A

BillionToOne Beats the Odds With $15 Million Series A

BillionToOne’s first product is a non-invasive prenatal test for recessively inherited single gene disorders.

Prellis Biologics raises $9 million for laser-printing organs

Prellis Biologics raises $9 million for laser-printing organs

Prellis is developing ultra-fast high-resolution holographic laser printing for creating human organs and tissues.

Meissa Vaccines Closes $3.4 Million Round to Advance RSV Vaccine to Clinic

Meissa Vaccines Closes $3.4 Million Round to Advance RSV Vaccine to Clinic

The Meissa team has developed a live attenuated vaccine with global utility.

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

OncoSynergy submits FDA application for clinical trial of therapy for malignant brain cancer

Glioblastoma is the most common primary brain cancer in adults.

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Last year, Alector advanced two drugs into early-stage clinical testing.

Epalex gets backing for migraine, epilepsy treatments

Epalex gets backing for migraine, epilepsy treatments

Epalex is a member of the 2017 Biotech/Biopharma Pitch Summit cohort.

Maria Artunduaga named Entrepreneur of the Year

Maria Artunduaga named Entrepreneur of the Year

Respira is building a service platform of wearable devices and adaptive digital algorithms to improve the delivery of Chronic Lower Respiratory Disease care.

Zymergen lands $400 million more, led by SoftBank Vision Fund, for its genetically altered microbes

Zymergen lands $400 million more, led by SoftBank Vision Fund, for its genetically altered microbes

The biggest opportunity for the 600-person company is to produce entirely new products that are untethered to traditional petroleum-based manufacturing.

Mission Bio raises Series B for single-cell sequencing

Mission Bio raises Series B for single-cell sequencing

The funding will enable the startup to expand its technology's role in discovering therapies for blood cancers and developing gene-editing technologies.